Kadmon Pharmaceuticals Doses First Patient in Phase 1b/2a Study of KD020 in Polycystic Kidney Disease
10/24/2012 8:44:14 AM
More...
|
Dyax Corp. (DYAX) and Kadmon Pharmaceuticals Sign Strategic Licensing Agreement for DX-2400
9/20/2012 9:27:13 AM
More...
|
Kadmon Pharmaceuticals Launches 600 mg/day Ribasphere(R) RibaPak(R) to Provide Added Dosing Control for Triple Therapy Treatment of Chronic Hepatitis C
6/5/2012 9:13:01 AM
More...
|
Biodesix, Inc. Announces Phase 3 Clinical Trial Collaboration with Kadmon Pharmaceuticals
2/27/2012 6:30:18 AM
More...
|
Kadmon Pharmaceuticals Release: Pill Burden a Key Concern With New Chronic Hepatitis C Drugs
5/19/2011 8:48:48 AM
More...
|